SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response and its evasion by emerging viral variants and variant of concern (VOC) are unknown, but critical to understand reinfection risk and breakthrough infection following vaccination. Antibody immunoreactivi...

Full description

Saved in:
Bibliographic Details
Published inPLoS medicine Vol. 18; no. 7; p. e1003656
Main Authors Tea, Fiona, Ospina Stella, Alberto, Aggarwal, Anupriya, Ross Darley, David, Pilli, Deepti, Vitale, Daniele, Merheb, Vera, Lee, Fiona X. Z, Cunningham, Philip, Walker, Gregory J, Fichter, Christina, Brown, David A, Rawlinson, William D, Isaacs, Sonia R, Mathivanan, Vennila, Hoffmann, Markus, Pöhlman, Stefan, Mazigi, Ohan, Christ, Daniel, Dwyer, Dominic E, Rockett, Rebecca J, Sintchenko, Vitali, Hoad, Veronica C, Irving, David O, Dore, Gregory J, Gosbell, Iain B, Kelleher, Anthony D, Matthews, Gail V, Brilot, Fabienne, Turville, Stuart G
Format Journal Article
LanguageEnglish
Published San Francisco Public Library of Science 06.07.2021
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response and its evasion by emerging viral variants and variant of concern (VOC) are unknown, but critical to understand reinfection risk and breakthrough infection following vaccination. Antibody immunoreactivity against SARS-CoV-2 antigens and Spike variants, inhibition of Spike-driven virus-cell fusion, and infectious SARS-CoV-2 neutralization were characterized in 807 serial samples from 233 reverse transcription polymerase chain reaction (RT-PCR)-confirmed Coronavirus Disease 2019 (COVID-19) individuals with detailed demographics and followed up to 7 months. A broad and sustained polyantigenic immunoreactivity against SARS-CoV-2 Spike, Membrane, and Nucleocapsid proteins, along with high viral neutralization, was associated with COVID-19 severity. A subgroup of "high responders" maintained high neutralizing responses over time, representing ideal convalescent plasma donors. Antibodies generated against SARS-CoV-2 during the first COVID-19 wave had reduced immunoreactivity and neutralization potency to emerging Spike variants and VOC. Accurate monitoring of SARS-CoV-2 antibody responses would be essential for selection of optimal responders and vaccine monitoring and design.
Bibliography:new_version
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
I have read the journal’s policy and the authors of this manuscript have the following competing interests: FB has received honoraria from Biogen Idec and Merck Serono as invited speaker. The other authors have declared that no competing interests exist.
SGT, FB, ADK, and GVM also contributed equally to this work.
ISSN:1549-1676
1549-1277
1549-1676
DOI:10.1371/journal.pmed.1003656